China Coronavirus Vaccine: Chinese Covid-19 vaccine candidate appears safe, induces immune response, preliminary study finds | World News – Times of India

Advertisement

BEGIN ARTICLE PREVIEW:

BEIJING: Results from an early-phase clinical trial of a Chinese vaccine candidate, CoronaVac, revealed that the formulation appears safe and induces an antibody response in healthy volunteers aged 18 to 59 years. According to the findings of the phase 1/2 randomised clinical trial, published in The Lancet Infectious Diseases journal, the vaccine candidate could induce an antibody response in participants within 28 days of the first immunisation, by giving two doses 14 days apart. The researchers, including those from the Jiangsu Provincial Center for Disease Control and Prevention in China, also found the optimum dose to generate the highest antibody responses, while taking account of side effects and production capacity. While the average levels of neutralising antibodies induced by CoronaVac was lower than levels seen in people who have previously had COVID-19, the scientists still believe the formulation could provide sufficient protection against the virus based on their experience with other vaccines and data from animal model studies. Since the study only included healthy adults aged 18 to 59 years, the researchers said further studies will be needed to test the vaccine candidate in other age groups, as well as in people with pre-existing medical conditions. “Our findings show that CoronaVac is capable of inducing a quick …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE